Global Blood Therapeutics (GBT) is a pharmaceutical company with focus on medical advancements for Sickle Cell Disease. Sickle Cell Disease is their only current disease focus and in 2019 they created one of two new medications that recently came to market. Voxelotor is the first hemoglobin oxygen-affinity modulator. Many patients in Nevada have benefited from this new medication since its release and it is one of the medications that SCCNV makes available as an option for its patients.
